The Vγ9Vδ2 T cells are specially adapted for tumor immunity through potent and broad tumor cytotoxicity, MHC-independency, relative resilience to the suppressive role of programmed cell death-1 (PD-1), low IL-17A production, and activation of NK cells cytotoxicity [18]. The gene discussed is IL17A; the disease is neoplasm.